Synthetic Biologics (SYN) Peer Comparison
$0.70
$-0.02
(-2.78%)
As on 05-Dec-2022 09:30EDT
Market cap
$16 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Edit
| Synthetic Biologics (SYN) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
16 | 16,765 | 13,492 | 12,332 | 11,994 |
Revenue ($ Mln) |
-- | 2,782 | 2,436 | 1,284 | 670 |
Net Profit ($ Mln) |
-19.36 | 491.50 | 860.62 | -325.10 | -319.95 |
Net Margin (%) |
-- | 17.67 | 35.33 | -25.32 | -47.79 |
RoE (%) |
-30.68 | 110.09 | 42.98 | -57.72 | -71.14 |
Price to Earnings |
-- | 35.25 | 17.40 | -- | -- |
Price-To-Book |
0.24 | 39.29 | 7.42 | 23.98 | 26.87 |
Income Statement ($ Mln)
| Synthetic Biologics (SYN) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 1,142.38 | 1,434.97 | 0.00 | 138.29 |
|
Cost of Revenue
|
0.00 | 814.22 | 52.87 | 0.41 | -- |
|
Gross Profit
|
-- | 328.16 | 1,382.10 | 0.00 | 138.29 |
|
Operating Expenses
|
19.52 | 129.54 | 1,095.43 | 242.48 | 287.32 |
|
Operating Profit (EBIT)
|
-19.52 | 198.62 | 286.67 | -242.48 | -149.04 |
|
Other Income
|
0.00 | 3.34 | -0.18 | 0.36 | 2.07 |
|
Profit before Tax
|
-19.36 | 201.85 | 294.15 | -241.85 | -140.85 |
|
Provision for Tax
|
0.00 | 20.00 | 63.09 | -0.77 | 0.00 |
|
Profit after Tax (Net Income)
|
-19.36 | 181.85 | 231.06 | -241.08 | -140.85 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
-14.50 | 181.85 | 231.06 | -241.85 | -140.85 |
Liabilities ($ Mln)
| Synthetic Biologics (SYN) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
58.15 | 952.93 | 2,210.62 | 196.11 | 408.82 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
7.35 | 149.79 | 68.03 | 0.39 | 154.79 |
|
Current Liabilities
|
13.19 | 557.22 | 337.59 | 76.84 | 146.54 |
|
Total Liabilities
|
70.37 | 1,659.94 | 2,616.24 | 273.33 | 710.15 |
Assets ($ Mln)
| Synthetic Biologics (SYN) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
25.96 | 969.02 | 781.49 | 1.65 | 325.55 |
|
Current Assets
|
52.73 | 690.91 | 1,834.75 | 271.68 | 384.60 |
|
Total Assets
|
70.37 | 1,659.94 | 2,616.24 | 273.33 | 710.15 |
|
Total Debt*
|
0.00 | 130.97 | 51.27 | 0.80 | 25.55 |
|
Net Current Assets
|
39.54 | 133.70 | 1,497.16 | 194.85 | 238.06 |
Cashflow ($ Mln)
| Synthetic Biologics (SYN) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-12.89 | 263.33 | 400.80 | -183.92 | 171.31 |
|
Cash Flow from Investing Activities
|
-0.01 | -31.36 | -42.88 | -5.06 | -141.68 |
|
Cash from Financing Activities
|
74.00 | -44.45 | -14.80 | 171.24 | 11.31 |
|
Net Cash Inflow / Outflow
|
-- | 187.51 | 52.64 | -17.74 | 40.85 |
Ratios
Profitability Ratios
| Synthetic Biologics (SYN) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-37.82 | 18.14 | 11.03 | -110.17 | -30.71 |
|
ROE (%)
|
-30.68 | 20.68 | 11.30 | -110.57 | -32.36 |
|
ROA (%)
|
-22.75 | 11.92 | 9.72 | -86.05 | -22.85 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | 15.87 | 16.10 | -66,412.67 | -100.35 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Synthetic Biologics (SYN) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.23 | 0.45 | -- | 0.57 |
|
EBIT Growth (%)
|
-29.88 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-74.18 | 25.08 | 106.71 | -22.10 | -66.58 |
|
EPS Growth (%)
|
-- | 0.25 | 1.04 | -0.11 | -0.64 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Synthetic Biologics (SYN) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 45.17 | 25.57 | -6.00 | -46.33 |
|
Price / Book Value
|
-- | 8.62 | 2.67 | 7.38 | 15.96 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
4.64 | 35.34 | 14.96 | -4.86 | -46.64 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Synthetic Biologics (SYN) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.14 | 0.02 | 0.00 | 0.06 |
|
Short term debt to equity ratio
|
0.00 | 0.17 | 0.00 | 0.00 | 0.01 |
|
Current Ratio
|
4.00 | 1.24 | 5.43 | 3.54 | 2.62 |
|
Quick Ratio
|
4.00 | -- | 5.35 | -- | 2.59 |
|
Interest Coverage
|
-644.23 | 1,923.40 | -- | -232.93 | -23.01 |
Operating Efficiency Ratios
| Synthetic Biologics (SYN) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Madrigal Pharmaceuticals (MDGL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 16.32 | 19.70 | -- | 7.42 |
|
Asset Turnover
|
0.00 | 0.75 | 0.60 | 0.00 | 0.22 |
|
Receivable days
|
-- | 55.54 | 56.45 | -- | 14.66 |
|
Inventory Days
|
-- | 0.00 | 167.40 | -- | -- |
|
Payable days
|
-- | 11.71 | 165.41 | 10,099.39 | -- |
|
Cash Conversion Cycle
|
-- | 48.64 | 58.44 | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
